|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Overtreatment of Prostate Cancer Persists in Men with Limited Life Expectancy |
| Timothy Daskivich, MD |
| Zachary Klaassen hosts Timothy Daskivich to discuss a JAMA Internal Medicine publication on prostate cancer overtreatment among men with limited longevity in the active surveillance era. |
|
|
|
|
|
|
|
|
|
|
|
|
Integrating Genomic Testing with MRI Enhances Stratification of Surveillance Patients
|
Mark Sultan, MD, and Eric Kim, MD
Mark Sultan and Eric Kim discuss research on predicting prostate cancer progression during active surveillance using Decipher® genomic classifier scores and MRI characteristics.
|
|
|
|
|
|
|
|
|
|
|
| Early Palliative Care Boosts Quality of Life for Prostate Cancer Patients |
| Michael Rabow, MD, FAAHPM |
| Michael Rabow joins Ruchika Talwar to discuss the benefits of early palliative care intervention in prostate cancer patients. Dr. Rabow highlights four key advantages: improved patient and caregiver satisfaction, better symptom management, enhanced care efficiency with reduced costs, and potential life prolongation. |
|
|
|
|
|
|
|
|
|
|
|
| Clinical Progression of Prostate Cancer from Active Surveillance is Predicted by Decipher® Genomic Classifier Score on Index Biopsy Independent from Risk Assessment by MRI Characteristics
|
| Mark Sultan, MD
|
| Mark Sultan presented findings that the Decipher® Genomic Classifier (GC) score from the index biopsy is an independent predictor of clinical progression in active surveillance for prostate cancer, even when adjusted for initial mpMRI results. The study found that a Decipher® GC score of ≥0.45 was significantly associated with an increased risk of progression to treatment, whereas mpMRI findings alone (PI-RADS 4-5 lesions) did not predict progression in patients with high Decipher® scores.
|
|
|
|
|
|
| Prostate Cancer Screening with Biomarkers and MRI–A European Perspective |
| Tobias Nordström, MD |
| Tobias Nordström discussed prostate cancer screening strategies from a European perspective, highlighting the role of biomarkers and MRI. He presented evidence from trials like the Göteborg and ERSPC studies, which showed that PSA screening reduces prostate cancer mortality, though with varying outcomes. Dr. Nordström emphasized the value of integrating biomarkers like Stockholm3 with PSA and MRI to improve screening efficiency, reduce unnecessary biopsies, and maintain detection of clinically significant cancers. |
|
|
|
|
|
|
|
|
|
|
| AI in Prostate Cancer: Diagnostic Hype and Hope
|
| Anobel Y. Odisho, MD, MPH, FAMIA
|
| Anobel Odisho's presentation at the 2024 SUO meeting highlighted the role of AI in prostate cancer diagnosis, focusing on its applications in prostate MRI for improving image quality, lesion detection, and risk stratification, as well as in pathology for cancer detection and risk prediction. While AI has shown promising results, including outperforming radiologists in lesion classification, challenges remain in data handling, trust, and clinical integration. Future efforts will focus on refining AI models for clinical use, addressing technical and workflow barriers.
|
|
|
|
|
|
| Patient-Reported Outcome Measures and Experience Measures After Active Surveillance Versus Radiation Therapy Versus Radical Prostatectomy for Prostate Cancer: A Systematic Review of Prospective Comparative Studies - Beyond the Abstract |
| Andrea Alberti, Rossella Nicoletti, Daniele Castellani et al. |
| This systematic review compared patient-reported outcome measures and experience measures after three common treatments for localized prostate cancer: radical prostatectomy (RP), radiation therapy (RT), and active surveillance. The findings revealed that RP significantly impacts urinary continence and sexual function, while RT mostly affects bowel function and voiding symptoms. |
|
|
|
|
|
Patients' Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER Study - Beyond the Abstract
|
| Martin J. Connor PhD, FHEA, MRCS, MSc, BSc (Hons), MBBS |
| The IP5-MATTER study investigated patients' preferences for additional cytoreductive treatments in de novo metastatic prostate cancer, focusing on their trade-offs between treatment toxicity and survival benefits. The study, conducted across multiple UK centers, found that most patients were willing to accept treatments that increased the risk of side effects like urinary incontinence and fatigue in exchange for improved survival and progression-free periods. Specifically, patients prioritized treatments that preserved urinary function and reduced fatigue. |
|
|
|
|
|
Understanding the Incidence, Duration, and Severity of Symptoms Through Daily Symptom Monitoring Among Frail and Non-Frail Older Patients Receiving Metastatic Prostate Cancer Treatments - Beyond the Abstract
|
| Ferozah Nasiri, Kian Godhwani, Milothy Parthipan, MScPT, & Shabbir M. H. Alibhai, MD, MSc |
| The study examined the daily symptom burden of older adults with metastatic prostate cancer (mPC) undergoing treatment with chemotherapy, androgen receptor axis therapy (ARAT), or radium-223. It found that frail older adults experienced more severe symptoms, such as fatigue, insomnia, and pain, for longer durations compared to non-frail adults. While chemotherapy patients showed significant improvements in well-being, pain, and fatigue, patients on ARAT or radium-223 did not. |
|
|
|
|
|
|
|
|
|
|
